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    Proliferative diabetic retinopathy (PDR) is the most common cause of severe visual loss in 
people with diabetes. Although panretinal photocoagulation (PRP) remains one of the best treatment, it has many side effects. So 
other new treatment modalities have emerged. These  can be used to increase the extent of treatment, expedite the effect of laser 
treatment and provide alternate measures when laser delivery is difficult or impossible, especially in patients with vitreous 
haemorrhage, or when the patient is at young age.  Currently, most of the research in this field is focussed on inhibitors of vascular 
endothelial growth factor (VEGF). Although limited by their short-lived effects, anti-VEGF agents are widely available, especially 
for the treatment of aggressive PDR. We present 2 cases which  had regression of neovascularization within  four weeks of the 
initial treatments, and  maintained their visual acuity with no evidence of recurrent neovascularization through 12 months after 
initiating treatment. Intravitreous injections of anti-VEGF therapy may be an alternative treatment option for patients with PDR. 
We followed  a system of 3 injection q4wk followed by injection q8wk,  depending on gravity of macular edema and it‘s regression 
from anti-VEGF intravitreal injections.   
 
Introduction  
Diabetic retinopathy is a disorder of the retinal vessels that eventually develops to some degree 
in nearly all patients with long-standing diabetes mellitus. Contributes 4.8% of the 37 million 
cases of blindness throughout the world. Most Common cause of bilateral severe visual loss in 
working age group. After 20 years of diabetes, nearly 99% of patients with  type 1 diabetes  and 
60% with type 2 have some degree on diabetic retinopathy. 33% of patients with diabetes have 
signs of diabetic retinopathy. People with diabetes are 25 times more likely to become blind than 
the general population. The  best predictor of diabetic retinopathy is the duration of the disease.  
Risk factors  for diabetic retinopathy: Age at diagnosis of diabetes; Duration; Poor control of 
diabetes; Pregnancy; Hypertension; Nephropathy; Hyperlipidemia; Obesity; Anemia; Smoking; 
Cataract surgery. 
Pathophysiology 
Diabetic Retinopathy is a microvasculopathy that causes: Retinal capillary occlusion and  
Retinal capillary leakage.  
 Microvascular occlusion is caused by: Thickening of capillary basement membranes; 
Abnormal proliferation of capillary endothelium; Increased platelet adhesion; Increased blood 
viscosity; Defective fibrinolysis. 
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Microvascular leakage is caused by: Impairment of endothelial tight junctions; Loss of 
pericytes; Weakening of capillary walls; Elevated levels of vascular  endothelial growth factor 
(VEGF). 
Overtime, retinal capillary closure can occur, and parts of the retina may become ischemic. 
VEGF released by the ischemic retina can stimulate the growth of abnormal capillaries, termed 
neovascularization at the disc or elsewhere in the retina, which are features of proliferative 
diabetic retinopathy (PDR). VEGF also can cause hyperpermeability ofretinal vessels,which can 
lead to vision loss from diabetic macular edema (DME), i.e.,swelling or thickening of the center of 
the retina. Panretinal photocoagulation (PRP), which destroys part of the ischemic retina, thus 
reducing the release of VEGF, is the standard treatment for PDR. Close to 60% of patients show 
regression of neovascularization within 3 months of PRP treatment.  However, there are many 
adverse effects of PRP, including pain, decreased peripheral and night vision, increased risk of 
macular edema, and progression of visual loss in nearly 5%  of patients despite treatment.  
Decreased peripheral and night vision are unavoidable side effects to this destructive procedure so 
it should be avoided as long as it can, especially on young ages due to lost of peripheral and night 
vision.   
Case presentation 1 
B.T a 69 year old man who has been treated with insulin for the last 18 years presented at our 
clinic after his endocrinologist asked him so. After the examination it was noted an advanced 
diabetic retinopathy. His visual acuity was 2/20 OD, and 4/20 on OS. Oct showed severe diabetic 
macular edema on both eyes (figure 1) and fluorescein angiography showed capillary non 
perfusion on periphery of the retina.  We performed panretinal photo coagulation (PRP) (figure 2) 
combined with 3 injection of intravitreal aflibercept 40mg/ml q4wk.  After 4 months we noticed a 
good regression of macular edema on OCT and the patient gained a VA of about 30% on his right 
eye and 35% on his left eye (figure 3). We performed intravitreal injection of aflibercept q8wk on 
both eyes for the next 8 months, and managed to maintain his visual acuity on  6/20 on OD and 
7/20 on OS after one year with no change on macular edema.  
Case presentation 2  
K.H is 67 years old man with history of uncontrolled diabetes for more than 5 years. He 
presented at our clinic due to his blurred vision in the last 2 months. After the examination he was 
diagnosed with proliferative diabetic retinopathy in both eyes with severe macular edema(figure 
4). Immediately we performed  intravitreal injection of aflibercept in both eyes, followed by 2 
more injection in the next 2 months. He had a good response and a reduction of the macular edema 
from 785m to 534m  on his right eye to the macular thickness, and from 583m  to 420m to his 
left eye (figure 5). After that, we continued the intravitreal  injection  af aflibercpt every next 
month. 12 months after we had a very good and stabilized situation for the patient. OCT showed   
a macular thickness  217m on his right eye with BCVA 8/20 and 266m  on his left eye with 
BCVA 7/20 (figure 6).  
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Discussion  
Anti-VEGF agents are  known to be effective in the treatment of ocular neovascularization 
associated with age-related macular degeneration, and  have  been proven to be superior to 
macular laser for treating diabetic macular edema,  and have the potential to be effective in other 
neovascular processes of the eye such as PDR. It may not be possible to proceed with the 
panretinal photocoagulation (PRP),  unless you find huge zones of capillary non perfusion. You 
should avoid or at list postponed  PRP  especially if the patients are young and want to save their 
peripheral and night vision. Using anti-VEGF may keep the situation stabilized with a good and 
promising visual acuity performing injection every next month.  
Conclusion  
Diabetic retinopathy is a disorder of the retinal vessels and the most Common cause of 
bilateral severe visual loss in working age. 
Best available treatment for PDR is panretinal photocoagulation (PRP) and intra vitreal 
injection of anti-VEGF.  
PRP  has many adverse effects including pain, decreased peripheral and night vision, increased 
risk of macular edema, and progression of visual loss in nearly 5 percent of patients despite 
treatment. 
Intravitreal injection of Anti-VEGF may be the safes and best solution in treatment of diabetic 
macular edema for the long term.   
 
Figure 1 
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Figure 2 
 
Figure 3 
 
figure 4 
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Figure 5. 
 
Figure 6. 
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